GlassScriptPhysician profile
Sarah Bivens Mills
NPI 1831417534
$6,885.85
in general payments reported to CMS, 2019-2025
59 companies · $2,314 in 2025
The $2,314 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $1,376 · 2023: $1,437 · 2024: $1,654 · 2025: $2,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,187 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,186.89 |
| Education | $217.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $448.11 | 2022-2025 | Tecvayli, Erleada, Darzalex |
| Genentech USA, INC. | $415.33 | 2023-2025 | Tecentriq, Polivy, Alecensa |
| Eisai INC. | $357.77 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $325.08 | 2022-2025 | Fotivda |
| Tersera Therapeutics LLC | $320.57 | 2022-2025 | Zoladex |
| Novartis Pharmaceuticals Corporation | $303.02 | 2021-2025 | |
| Genzyme Corporation | $238.87 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $235.57 | 2022-2025 | Lynparza, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $233.88 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Abbvie INC. | $208.15 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $203.39 | 2022-2025 | Iclusig, Alunbrig, Vpriv |
| Lilly USA, LLC | $201.83 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $191.64 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $183.38 | 2022-2025 | Onivyde, Somatuline Depot, Tazverik |
| Sobi, INC | $171.33 | 2022-2024 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $154.43 | 2025 | Brukinsa, Tevimbra |
| Regeneron Healthcare Solutions, INC. | $150.98 | 2022-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $143.31 | 2022-2025 | |
| Astellas Pharma US INC | $125.91 | 2022-2024 | Padcev, Xospata, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $124.39 | 2022-2025 | Opdivo, Augtyro, Krazati |
| Genmab U.S., INC. | $117.84 | 2023-2025 | Epkinly |
| Rigel Pharmaceuticals, INC. | $110.24 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Beigene USA, INC. | $106.56 | 2022-2024 | Brukinsa, Tevimbra |
| Gilead Sciences, INC. | $105.05 | 2024-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $103.98 | 2022-2025 | Besremi |
| Daiichi Sankyo INC. | $102.16 | 2025 | Datroway, Enhertu |
| Amgen INC. | $101.20 | 2021-2023 | Blincyto, Kyprolis |
| G1 Therapeutics, INC. | $94.30 | 2022-2023 | Cosela |
| Puma Biotechnology, INC. | $91.58 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $90.42 | 2022-2023 | Imbruvica, Epkinly |
| Emd Serono, INC. | $80.20 | 2023-2025 | Bavencio |
| Servier Pharmaceuticals LLC | $79.50 | 2022 | |
| Seagen INC. | $76.35 | 2022-2023 | Tukysa, Padcev |
| Blueprint Medicines Corporation | $71.94 | 2023-2025 | Ayvakit |
| Celgene Corporation | $68.57 | 2022-2025 | Reblozyl |
| Exelixis INC. | $67.82 | 2021-2025 | Cabometyx |
| Agios Pharmaceuticals, INC. | $66.18 | 2023-2024 | Pyrukynd |
| Mirati Therapeutics, INC. | $62.99 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $51.79 | 2025 | Orserdu |
| Caris Mpi, INC. | $43.44 | 2025 | Mi Cancer Seek |
| Geron Corporation | $39.95 | 2025 | Rytelo |
| Taiho Oncology, INC. | $36.72 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $36.41 | 2023-2024 | Monoferric |
| Array Biopharma INC | $33.35 | 2023 | Lorbrena, Mektovi, Xalkori |
| Glaxosmithkline, LLC. | $33.03 | 2023-2024 | Shingrix, Jemperli, Zejula |
| Amag Pharmaceuticals, INC. | $28.25 | 2021-2022 | |
| Legend Biotech USA INC. | $27.36 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $23.45 | 2022 | |
| Octapharma USA, INC. | $23.00 | 2025 | Octagam Immune Globulin (Human) |
| Kite Pharma, INC. | $22.01 | 2025 | Yescarta |
| Adc Therapeutics America, INC. | $19.53 | 2024 | |
| Recordati_rare_diseases_inc. | $18.90 | 2025 | Enjaymo |
| Macrogenics, INC. | $18.70 | 2022 | |
| Secura Bio, INC. | $18.26 | 2023 | Copiktra |
| Apellis Pharmaceuticals, INC. | $17.51 | 2022 | |
| Immunocore Limited | $16.54 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.32 | 2023 | Givlaari |
| Kyowa Kirin, INC. | $14.81 | 2023 | Poteligeo |
| Iovance Biotherapeutics, INC. | $13.70 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.